Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)

Novartis argues India’s interpretation of the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights agreement is too strict and focuses too much on efficacy to the exclusion of bioavailability.